三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

已收盘 09-28 16:08:28

15.620

-0.360

-2.25%

最高16.240	最低15.520	成交量1,486万
今开15.970	昨收15.980	日振幅4.51%
总市值393.78亿	流通市值393.78亿	总股本25.21亿
成交额2.34亿	换手率0.59%	流通股本25.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":15.62,"timestamp":1790582908002,"preClose":15.98,"halted":0,"volume":14863012,"delay":0,"changeRate":-0.022528160200250388,"floatShares":2521000000,"shares":2521000000,"eps":4.006675897234752,"marketStatus":"已收盘","change":-0.36,"latestTime":"09-28 16:08:28","open":15.97,"high":16.24,"low":15.52,"amount":233763287,"amplitude":0.045056,"askPrice":15.62,"askSize":22500,"bidPrice":15.55,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":3.7952530719670525,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790645400000},"marketStatusCode":5,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":15.98,"dividendRate":0.016841,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":0.789074,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBI.HK","impliedVol":0.0726,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2670235746","title":"三生制药(01530)9月28日斥资2041万港元回购130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670235746","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670235746?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:03","pubTimestamp":1790589820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，该公司于2026年9月28日斥资2041万港元回购130万股股份，每股回购价格为15.6-15.8港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HELS","BK1583","BK1593","BK1161","HK0000165453.HKD","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172568926","title":"三生制药：9月28日回购130万股股份，总额约2,041.00万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172568926","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172568926?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:02","pubTimestamp":1790589739,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月28日发布翌日披露报表，公告当日通过香港联合交易所场内回购1,300,000股普通股股份，约占该公司已发行股本0.05%。每股回购价格介乎15.60港元至15.80港元，合计涉资20,410,000港元。回购完成后，公司已发行股份总数由2,521,088,412股变动为2,519,788,412股，库藏股数增至18,476,000股。三生制药方面确认，此次回购严格遵守香港联合交易所证券上市规则及相关法律法规，符合所有适用规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：9月28日回购130万股股份，总额约2,041.00万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192995461","title":"异动解读｜三生制药盘中下跌5.06%，报16.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192995461","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192995461?lang=zh_cn&edition=full","pubTime":"2026-09-24 14:03","pubTimestamp":1790229829,"startTime":"0","endTime":"0","summary":"9月24日，三生制药盘中下跌5.06%，报16.15港元/股，成交额1.49亿港元。三生制药所在的生物科技行业整体承压，个股中，信达生物跌3.72%，康方生物跌4.26%，诺诚健华跌11.17%，百济神州跌1.92%，荣昌生物跌8.25%。三生制药是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，同时开展CDMO业务，产品主要应用于血小板减少症、慢性肾病引起的贫血症等领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669548376","title":"三生“少帅”娄竞：从科学家到操盘手，是药二代更是创一代","url":"https://stock-news.laohu8.com/highlight/detail?id=2669548376","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669548376?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:02","pubTimestamp":1790164971,"startTime":"0","endTime":"0","summary":"三生官方资料将其列为益比奥、特比澳开发的领导科学家和主要研究员。2007年三生制药登陆纳斯达克，是国内较早赴美上市的生物药企之一。2015年三生回港上市，公司大事记称其当年成为全球生物制药领域受关注IPO之一。娄竞接手后先扩后收，早期保留赛普汀等肿瘤抗体，2020年前后逐步把资源收回到自身免疫。国健年报披露，相关款项三生国健占30%、沈阳三生占70%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790134731525398876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["HK0000165453.HKD","688336","01530","BK1161","BK0239","BK1593","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669119340","title":"【券商聚焦】兴业证券维持三生制药（01530）增持评级 指核心经营质量改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2669119340","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669119340?lang=zh_cn&edition=full","pubTime":"2026-09-22 14:24","pubTimestamp":1790058242,"startTime":"0","endTime":"0","summary":"金吾财讯 | 兴业证券发布研报指，三生制药 发布2026年中期业绩公告。归母净利润下降主要受汇兑净损失等非经营性因素影响，经调整经营性归母净利率升至31.7%，核心经营质量持续改善。截至2026年8月，辉瑞已开展9项全球多中心临床试验，其中2项III期、3项II期和4项I期；SSGJ-707已注册11项研究，覆盖23个国家及地区，已启动1361家临床中心，预计入组5016例患者。2027年公司计划推动SSGJ-610提交NDA，多款产品有望获批上市。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992190","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","601377","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669549132","title":"港股午盘｜恒指涨0.56% 创新药概念股走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2669549132","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669549132?lang=zh_cn&edition=full","pubTime":"2026-09-21 12:04","pubTimestamp":1789963446,"startTime":"0","endTime":"0","summary":"恒指涨0.56%，恒生科技指数跌0.13%，创新药概念股走强，康方生物涨近9%，科伦博泰生物涨近8%，三生制药涨逾6%。黄金股普跌，中国黄金国际跌逾7%，灵宝黄金跌近5%，山东黄金、紫金黄金国际跌逾3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202609213879859453.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202609213879859453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348767384.USD","LU1242518931.SGD","513600","LU2213484517.USD","02800","01787","IE00B543WZ88.USD","LU0540923850.HKD","LU0348735423.USD","LU0561508036.HKD","09926","LU0348827113.USD","LU0417516571.SGD","02833","LU0417516902.SGD","09115","LU0181495838.USD","LU0348784397.USD","SGXZ62798434.SGD","06990","LU0348766576.USD","LU0828237940.HKD","LU0463099449.HKD","IE00BPRC5H50.USD","LU1831875114.USD","HHImain","LU0140636845.USD","07200","LU0634319403.HKD","03330","600547","SGXZ86797644.SGD","HK0000500386.USD","LU1242518857.USD","SG9999003461.SGD","LU1171460220.USD","LU2399975544.HKD","03037","07500","LU0244354667.USD","LU0417516738.SGD","BK1574","HSI","82800","01530","LU0348783233.USD","BK1544","02259","HK0000252160.HKD","LU0314109678.HKD","BK1198","LU1961090484.USD","LU0979878070.USD","LU1794554557.SGD","BK1593","MCHmain","LU2476274720.SGD","03419","LU2488822045.USD","LU2039709279.SGD","LU2279858448.HKD","BK1592","HSTECH","LU0593848301.USD","JINFF","83115","LU1328277881.USD","02099","LU2778985437.USD","LU1188198961.HKD","LU2476274308.USD","KURE","LU0326950275.SGD","MHImain","LU1720050803.USD","LU1813983027.USD","LU2543165471.USD","03115","IE00B5MMRT66.SGD","LU0196878994.USD","HK0000165453.HKD","BK1161","BK1583","HK0000252152.HKD","SG9999001093.SGD","LU0348825331.USD","07300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669509139","title":"医美概念股多股上扬 三生制药（01530）涨5.71%、四环医药（00460）涨4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669509139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669509139?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:09","pubTimestamp":1789956581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股多股上扬，截至发稿，山东新华制药股份 涨10.81%，三生制药涨5.71%，四环医药涨4.17%，昊海生物科技涨3.82%，复星医药涨3.12%，现代牙科涨3.10%，时代天使涨2.25%。消息面上，国金证券表示，医美板块下游连锁景气回暖，上游平台化逻辑有望兑现，建议关注上游头部连锁化机构、需求扩容下具备强渠道能力的上游平台化标的。看好布局差异化赛道的上游医美产品厂商及满足医美新场景需求的下游医美机构。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","06826","BK1583","02196","BK1161","BK1587","00719","BK1600","03600","00460","BK1100","BK1191","01530","HK0000165453.HKD","06699","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127607565","title":"异动解读｜三生制药盘中上涨5.21%，持续回购叠加机构增持提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1127607565","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127607565?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:45","pubTimestamp":1789955151,"startTime":"0","endTime":"0","summary":"9月21日，三生制药盘中上涨5.21%，报16.57港元，成交额8596.13万港元。消息面上，公司近期持续大手笔回购股份，仅9月以来已累计实施6次回购，合计回购约865.55万股，耗资约1.36亿港元。今年以来公司已合计回购9次，累计金额约2.71亿港元，彰显管理层对公司价值的信心。此外，公司董事长娄竞于9月7日以每股16.0港元增持49万股，贝莱德亦于近期增持约4760万股，机构与管理层同步加仓形成共振。公司核心品种SSGJ-707与辉瑞的全球临床推进被视为主要上行催化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药盘中上涨，回购与增持共振","news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146270840","title":"三生制药：9月18日回购106.55万股，耗资约1,688.16万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146270840","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146270840?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:21","pubTimestamp":1789726867,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月18日公告称，公司于当日在香港联交所场内回购普通股1,065,500股，约占此前已发行股份总数的0.04%。本次回购价格区间为每股15.75港元至15.90港元，合计金额为16,881,625港元，折合约1,688.16万港元。另根据公告，本次回购后，公司将于2026年10月18日前暂停发行新股及出售或转让任何库存股份。公司在公告中表示，已遵守香港联合交易所有限公司证券上市规则及相关法律规定。本次回购事项的公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：9月18日回购106.55万股，耗资约1,688.16万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668478299","title":"三生制药(01530)9月18日斥资1688.16万港元回购106.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668478299","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668478299?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:17","pubTimestamp":1789726657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月18日，该公司斥资1688.16万港元回购106.55万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01530","HK0000165453.HKD","BK1161","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123184820","title":"三生制药9月16日回购170万股股份，耗资约2,677.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123184820","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123184820?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:41","pubTimestamp":1789555299,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月16日发布公告显示，公司当日于香港联交所以每股15.70至15.79港元的价格区间回购普通股1,700,000股，占该日前公司已发行股本约0.07%，合计耗资26,775,000港元。公告称，截至2026年9月14日，公司已发行股份总数为2,523,853,912股，库存股份数为14,410,500股。本次回购依据2026年6月25日获股东大会批准的购回授权实施，该授权规定公司可最多购回253,707,141股股份。公司确认已遵守香港联交所证券上市规则及相关法律法规。本公告由公司秘书黎少娟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药9月16日回购170万股股份，耗资约2,677.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667602772","title":"三生制药(01530.HK)9月16日斥资2677.5万港元回购170万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667602772","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667602772?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:35","pubTimestamp":1789554957,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1583","01530","BK1161","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110389318","title":"三生制药：9月14日回购20万股股份，耗资约309.40万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110389318","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110389318?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:16","pubTimestamp":1789380987,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月14日发布翌日披露报表，宣布开展股份回购。该公司于当日通过香港联交所场内方式，以每股15.47港元的价格回购普通股20万股，占回购前公司已发行股本约0.01%，合计支付金额3,094,000港元。回购授权于2026年6月25日获股东大会通过，可回购股份总数为253,707,141股。三生制药确认，此次股份回购符合《香港联合交易所有限公司证券上市规则》等相关法规。公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：9月14日回购20万股股份，耗资约309.40万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576906","title":"三生制药(01530)9月14日斥资309.4万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576906","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667576906?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:15","pubTimestamp":1789380928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月14日，该公司斥资309.4万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","HK0000165453.HKD","01530","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股异动 | 创新药概念股全线走高 WCLC临床数据重磅催化 机构指回调后配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667608630?lang=zh_cn&edition=full","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1961090484.USD","BK1593","09926","LU0348735423.USD","LU0634319403.HKD","KURE","LU0348827113.USD","159992","LU2488822045.USD","BK1191","HK0000165453.HKD","LU0244354667.USD","LU0455707207.USD","LNGR","LU1188198961.HKD","BK1574","LU0326950275.SGD","06978","KCAI","LU2242644610.SGD","01530","VXUS","LU0348784397.USD","LU0561508036.HKD","LU0348766576.USD","IBBQ","LU2097828557.USD","LU2097828805.USD","09969","LU2476274308.USD","IE00BPRC5H50.USD","LU0607220059.USD","MEDX","BK1589","LU0348825331.USD","LU0417516571.SGD","LU2778985437.USD","BK1161","LU0417516738.SGD","LU2476274720.SGD","IE00B543WZ88.USD","BK4588","LU1969619763.USD","01177","01801","LU2097828714.EUR","IE00BZ08YR35.GBP","LU0348767384.USD","LU1831875114.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117080279","title":"异动解读｜三生制药盘中上涨5.31%，连续大手笔回购叠加高管增持提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1117080279","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117080279?lang=zh_cn&edition=full","pubTime":"2026-09-14 11:05","pubTimestamp":1789355148,"startTime":"0","endTime":"0","summary":"9月14日，三生制药盘中上涨5.31%，报16.26港元，成交额1.38亿港元。消息面上，公司近期持续加大回购力度，9月10日单日斥资约6263万港元回购400万股，9月11日再度回购19万股；执行董事兼主席娄竞于9月7日以每股16.00港元增持49万股，涉资约784万港元，好仓比例升至21.13%。生物科技板块今日整体走强，康方生物涨6.7%、科伦博泰生物涨3.53%，板块情绪亦构成支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药盘中上涨，大手笔回购增持提振信心","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111186707","title":"三生制药回购19万股股份，耗资约288.08万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111186707","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111186707?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:16","pubTimestamp":1789121773,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月11日发布翌日披露报表，宣布当天在香港联交所场内回购公司普通股190,000股，占该日前现有已发行股本的约0.01%。回购价格介乎每股15.13港元至15.17港元，总支出2,880,820港元。该回购根据公司于2026年6月25日通过的购回授权进行，授权可回购股份总数为253,707,141股，截至目前公司已在港交所及其他证券交易所合计回购13,197,500股，约占购回授权通过时公司已发行股份的0.52%。公司确认此项回购行为已遵守香港联交所证券上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药回购19万股股份，耗资约288.08万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131586261","title":"三生制药：2026年9月10日回购400万股，耗资约6,262.93万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131586261","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131586261?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:41","pubTimestamp":1789036914,"startTime":"0","endTime":"0","summary":"2026年9月10日，三生制药（股票代码：01530）披露翌日报表，宣布于香港联交所场内回购普通股4,000,000股，约占该公司当日现有已发行股本的0.16%。本次回购价格介乎每股港元15.50至15.75，合计耗资约6,262.93万港元。回购完成后，公司已发行股份总数变动为2,524,243,912股，库藏股增加至14,020,500股。\n此前，公司已于2026年6月25日通过购回授权，可回购股份的总数为253,707,141股，迄今已累计回购13,007,500股。本次回购行为遵守香港联交所证券上市规则及适用法律规定。上述公告由公司秘书黎少娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：2026年9月10日回购400万股，耗资约6,262.93万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666673645","title":"三生制药(01530)9月10日斥资6262.93万港元回购400万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666673645","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666673645?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:36","pubTimestamp":1789036592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月10日，该公司斥资6262.93万港元回购400万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1161","BK1583","BK1593","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","03933","IE00BZ08YS42.EUR","01530","HK0000165453.HKD","BK1583","BK1161","IE00BZ08YT58.USD","BK1574","BK1593","IE00B3M56506.USD","BK1515","01477","BK1521","IE00BZ08YR35.GBP","BK1191","03692","01177","BK1589"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":-0.0884},{"period":"3month","weight":0.0193},{"period":"6month","weight":-0.3238},{"period":"1year","weight":-0.4721},{"period":"ytd","weight":-0.3294}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006634},{"month":2,"riseRate":0.454545,"avgChangeRate":0.001777},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113184},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080953},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025359},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.034677},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.015863},{"month":9,"riseRate":0.583333,"avgChangeRate":0.024464},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018318},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059928},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045348}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}